CoChat

Homocysteine Lowering and Cognition in CKD: The Veterans Affairs Homocysteine Study

Open access
Brady, Christopher B., Gaziano, J. Michael, Cxypoliski, Roberta A., Guarino, Peter D., Kaufman, James S., Warren, Stuart R., Hartigan, Pamela, Goldfarb, David S., Jamison, Rex L. · 2009 · American Journal of Kidney Diseases
Cited by 75

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Background Individuals with advanced chronic kidney disease (CKD) and end stage renal disease (ESRD) have high total plasma homocysteine (tHcy) levels, which may be a risk factor for cognitive impairment. Whether treatment with high dose B-vitamins to reduce high tHcy levels improves cognition in persons with kidney disease is unknown. Study Design Randomized controlled trial. Setting & Participants A substudy of 659 patients (mean age 67.3 ± 11.7 years) who participated in a randomized, double-blind, clinical trial, 5 years in duration, conducted in 36 US Department of Veterans Affairs medical centers, of the effect on all-cause mortality of vitamin-induced lowering of plasma tHcy. 236 (35.8%) were treated by dialysis (ESRD) and 423 (64.2%) had a Cockcroft-Gault estimated creatinine clearance ≤ 30 ml/min (advanced CKD). All had high tHcy levels (≥15 μmol/L) at baseline. Cognitive assessments began during the follow up period of the main trial, 3 years after treatment began; participants were subsequently retested one year later to assess cognitive change. Intervention Daily high dose B-vitamin capsule (40 mg of folic acid, 100 mg of vitamin B6, and 2 mg of vitamin B12) or placebo. Outcomes Cognitive function at initial assessment and one year later. Measurements The Telephone Interview of Cognitive Status – modified, supplemented with attention, working memory and executive function tests. Results Initial cognitive function was impaired in approximately 19% of patients, regardless of treatment assignment (vitamin or placebo) or kidney disease status (advanced CKD or ESRD). Treatment reduced tHcy levels by 26.7%. Unadjusted and adjusted analyses showed that treatment did not improve initial cognitive outcomes or affect subsequent cognitive status one year later. Limitations Cognitive assessments began after treatment was initiated; cognitive assessment was limited. Conclusion Treatment with high daily doses of B-vitamins, which reduced tHcy levels, did not affect cognitive outcomes in patients with advanced CKD and ESRD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.ajkd.2009.05.013

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 75

Metadata

Authors
Brady, C. B., Gaziano, J. M., Cxypoliski, R. A., Guarino, P. D., Kaufman, J. S., Warren, S. R., Hartigan, P., Goldfarb, D. S., & Jamison, R. L.
Venue
American Journal of Kidney Diseases
Publisher
Elsevier BV
Published
2009-09
Volume
54
Issue
3
Pages
440-449
ISSN
0272-6386 (ISSN-L)
OpenAlex
W2087146407
Cited by
75
References
7
FWCI
4.86
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Homocysteine Lowering and Cognition in CKD: The Veterans Affairs Homocysteine Study. https://app.cochat.ai/papers/10.1053/j.ajkd.2009.05.013
The paper
Brady, C. B., Gaziano, J. M., Cxypoliski, R. A., Guarino, P. D., Kaufman, J. S., Warren, S. R., Hartigan, P., Goldfarb, D. S., & Jamison, R. L. (2009). Homocysteine Lowering and Cognition in CKD: The Veterans Affairs Homocysteine Study. American Journal of Kidney Diseases. https://doi.org/10.1053/j.ajkd.2009.05.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.